Inoue M, Shimizu C, Sasagawa T, Shimizu H, Saitoh J, Ueda G, Tanizawa O, Kimura T, Kawata M, Taniguchi T
Department of Obstetrics and Gynecology, Osaka University Medical School.
Nihon Sanka Fujinka Gakkai Zasshi. 1987 Dec;39(12):2120-4.
In order to estimate the clinical significance of sialyl SSEA-1 antigen, the antigen was measured with an "FH-6" Otsuka Kit in sera from patients with various gynecologic tumors. Among the patients with uterine malignancies and benign ovarian tumors, the incidence of elevated sialyl SSEA-1 antigen levels was very low. However, among the patients with ovarian malignancies, serum sialyl SSEA-1 antigen was significantly increased in the following order: clinical stage I (40%), stage II (67%) and stage III (75%). The serum antigen values were also correlated with the effect of treatment. In addition, high antigen values were also observed in all 14 malignant ovarian cyst fluids tested. The immunohistochemical localization of sialyl SSEA-1 antigen was determined by an immunoperoxidase method using FH-6 monoclonal antibody. A weak positive reaction was observed in normal glands of female genital tracts. However, the intense staining was shown on the mocus materials or on the luminal surface of some malignant glands as well as in the cytoplasm of some adenocarcinoma cells of gynecologic malignancies, although there were few positive cases or positive cells. Thus, sialyl SSEA-1 antigen appears to be a useful marker in the diagnosis of ovarian malignancies.
为评估唾液酸化阶段特异性胚胎抗原-1（sialyl SSEA-1）抗原的临床意义，使用大塚“FH-6”试剂盒检测了各种妇科肿瘤患者血清中的该抗原。在子宫恶性肿瘤和卵巢良性肿瘤患者中，唾液酸化SSEA-1抗原水平升高的发生率非常低。然而，在卵巢恶性肿瘤患者中，血清唾液酸化SSEA-1抗原按以下顺序显著升高：临床I期（40%）、II期（67%）和III期（75%）。血清抗原值也与治疗效果相关。此外，在所检测的14例恶性卵巢囊肿液中均观察到高抗原值。采用FH-6单克隆抗体免疫过氧化物酶法确定唾液酸化SSEA-1抗原的免疫组化定位。在女性生殖道正常腺体中观察到弱阳性反应。然而，尽管阳性病例或阳性细胞很少，但在一些恶性腺体的病灶物质或腔表面以及妇科恶性肿瘤的一些腺癌细胞胞质中显示出强烈染色。因此，唾液酸化SSEA-1抗原似乎是卵巢恶性肿瘤诊断中的一个有用标志物。
